Protocol summary

Summary
The aim of our study was to compare the differences in pregnancy rates (PRs), implantation rates and miscarriage rates between a short agonist protocol with estradiol priming and a long protocol with combined OC. The inclusion criteria were as follows: women younger than 40 years old; an AMH level greater than 0.6 ng/mL; a body mass index between 18 and 29 kg/m2; and undergoing a first or second treatment cycle of IVF with intracytoplasmic sperm injection (ICSI). The exclusion criteria were endometriosis and preimplantation diagnosis cycles. After providing written consent, the 298 participants were randomly divided into one of the two study groups (154 patients who were treated with long GnRH agonist with combined OC pretreatment and 144 who weretreated with short GnRH agonist with estradiol pretreatment). The doctors performing the oocyte retrieval procedure and the embryologists involved were blind to the treatment groups. Our primary outcome measure was clinical pregnancy rate.

General information

Acronym
IRCT registration information
IRCT registration number: IRCT2015020418202N4
Registration date: 2015-02-27, 1393/12/08
Registration timing: retrospective

Last update:
Update count: 0
Registration date
2015-02-27, 1393/12/08
Registrant information
Name
Judyta Zabielska
Name of organization / entity
Invicta Sp.z o.o.
Country
Poland
Phone
0048 516 829 691
Email address
zabielska@gumed.edu.pl
Recruitment status
Recruitment complete
Funding source
Invicta sp.z o.o.
Expected recruitment start date
2013-07-01, 1392/04/10
Expected recruitment end date
2014-01-01, 1392/10/11
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Estradiol valerate pretreatment in short protocol GnRH-agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GnRH-agonist cycles: a randomised controlled trial
Public title
Comparison of short agonist vs long agonist stimulation protocol and different pretreatment s in women undergoing in vitro fertlization.
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion: women younger than 40 years old; an AMH level greater than 0.6 ng/mL; a body mass index between 18 and 29 kg/m2; first or second treatment cycle of IVF with intracytoplasmic sperm injection (ICSI). Exclusion: endometriosis; preimplantation diagnosis cycles
Age
From 18 years old to 40 years old
Gender
Female
Phase
N/A
Groups that have been masked
No information
Sample size
Target sample size: 298
Randomization (investigator's opinion)
Randomized
Randomization description
Blinding (investigator's opinion)
Single blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Bioethics Committee in Gdansk
Street address
ul. Sniadeckich 33
City
Gdansk
Postal code
80-204
Approval date
2013-03-26, 1392/01/06
Ethics committee reference number
Kb 9/13

Health conditions studied

1

Description of health condition studied
infertility
ICD-10 code
N97.9
ICD-10 code description
Female infertility, unspecified

Primary outcomes

1

Description
pregnancy rate
Timepoint
on 6 weeks and 1-3 days
Method of measurement
clinical poregnancy (as ultrasound fetal heartbeat detection)

Secondary outcomes

1

Description
implantation rate
Timepoint
7 days after tansfer
Method of measurement
blood serum beta-HCG concentration

Intervention groups

1

Description
Estradiol valerate pretreatment (2mg oral estradiol twice daily from the 20th day of cycle until 1-4th day of new cycle. in short protocol GnRH-agonist cycles (150-225 IU/day hMG continued with a daily dose of triptorelin 0.1 mg until the hCG injection - Chpragon 5000 administered 36 hours before retrieval.)
Category
Treatment - Drugs

2

Description
Combined pretreatment with oral contraceptive pills (Ovulostan from 2nd to 4th day of cycle) in long protocol GnRH-agonist cycles ( 0.1 mg Triptorelin beginning on the 14th day of the cycle, every 2 days, for two weeks, 150-225 IU/day hMG continued with a daily dose of triptorelin 0.1 mg until the hCG injection - Chpragon 5000 administered 36 hours before retrieval.)
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Invicta Fertility and Reproduction Centre
Full name of responsible person
Judytra Zabielska
Street address
City
Gdansk, Warsaw, Slupsk

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Invicta Fertility and Reproduction Centre sp.z o.o.
Full name of responsible person
Judyta Zabielska
Street address
Trzy lipy 3
City
Gdansk
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Invicta Fertility and Reproduction Centre sp.z o.o.
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact
Name of organization / entity
Invicta Fertility and Reproduction Centre sp.z o.o.
Full name of responsible person
Judyta Zabielska
Position
assistant
Other areas of specialty/work
Street address
Trzy lipy 3
City
Gdansk
Province
Gdansk
Postal code
Phone
0048585858800
Fax
Email
judyta.zabielska@invicta.pl
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Invicta Fertility and Reproduction Centre sp.z o.o.
Full name of responsible person
Judyta Zabielska
Position
assistant
Other areas of specialty/work
Street address
Trzy lipy 3
City
Gdansk
Province
Gdansk
Postal code
Phone
0048585858800
Fax
Email
judyta.zabielska@invicta.pl
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Invicta Fertility and Reproduction Centre sp. z o.o.
Full name of responsible person
Judyta Zabielska
Position
assistant
Other areas of specialty/work
Street address
Trzy lipy 3
City
Gdansk
Province
Postal code
80-172
Phone
0048 58 58 58 800
Fax
Email
judytazabielska@gmail.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty
Loading...